Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.30 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10014366 | 0.80 | LGALS3 (0.51) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL13321919 | 0.72 | BDNF (0.47) | LGALS3CD69LGALS7; LGALS7BLGALS1MMP9 | |
| SCHEMBL17678835 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL16258790 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL13839152 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL5357606 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL17681107 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL5357615 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL19976159 | 0.71 | LGALS3 (0.68) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B | |
| SCHEMBL19561674 | 0.70 | LGALS3 (0.58) | LGALS3LGALS8LGALS4CD69LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | LIPC, HAVCR2, LIPA | LGALS3 1079/4885LGALS8 1603/4885LGALS4 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.